Patents Represented by Attorney Pharmacia & Upjohn Company
  • Patent number: 6753163
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: June 22, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6740485
    Abstract: Staphylococcus aureus virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and provision of novel S. aureus mutants useful in vaccines.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: May 25, 2004
    Assignee: Imperial College Innovations Limited
    Inventors: David W. Holden, Ji Min Mei
  • Patent number: 6737510
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: May 18, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6727074
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: April 27, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6706485
    Abstract: The present invention provides methods of identifying agents that inhibit the amyloid precursor protein (APP) processing activity of Asp2 polypeptide.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: March 16, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6699671
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: March 2, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6699490
    Abstract: Prolonged parenteral release into the circulatory system of a cow of a bioactive bovine somatotropin at desirably effective levels can be achieved using novel compositions in which the bovine somatotropin is present in an aqueous liquid at a dose of at least about 150 mg and at a concentration of at least about 50 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than three (3) days.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: March 2, 2004
    Assignee: The Upjohn Co.
    Inventors: Michael John Hageman, Margaret Luise Possert
  • Patent number: 6689769
    Abstract: Substituted quinolone derivatives in which an oxazolidinone, isoxazolinone, or isoxazoline is covalently bonded to a quinolone, methods of using the quinolone derivatives, and pharmaceutical compositions containing the quinolone derivatives are disclosed. Methods of synthesizing these substituted quinolone derivatives are also disclosed, and in particular a method of manufacturing a 7-(2-oxo-1,3-oxazolidin-3-yl)aryl-3-quinolinecarboxylic acid by condensing a 4-(2-oxo-1,3-oxazolidin-5-yl)aryl boronic acid with a 7-halo-quinolone derivative. The quinolone derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: February 10, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mikhail F. Gordeev, Dinesh V. Patel, Michael R. Barbachyn, James R. Gage
  • Patent number: 6656470
    Abstract: The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: December 2, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Terry L. Bowersock, Paul Guimond, Tzu-Chi R. Ju, Argaw Kidane
  • Patent number: 6632621
    Abstract: The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.
    Type: Grant
    Filed: November 24, 2000
    Date of Patent: October 14, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Timothy G. Geary, Teresa M. Kubiak, Martha J. Larsen
  • Patent number: 6544991
    Abstract: A composition having antibacterial activity is disclosed. More particularly, a mixture of an oxazolidinone compound, sulbactam, and ampicillin active agents, demonstrating activity against resistant strains of bacteria is disclosed. Methods for using an oxazolidinone compound, sulbactam, and ampicillin to treat a bacterial infection are also described.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: April 8, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Donald H. Batts, Keiichi Hiramatsu